Pathophysiology of transfusional iron overload: Contrasting patterns in thalassemia major and sickle cell disease

Hemoglobin

Volumn 33, Issue SUPPL. 1, 2009, Pages

  Porter, John B ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Blood transfusion; Iron overload; Iron toxicity; Pathophysiology; Sickle cell disease; Thalassemia

Indexed keywords

DEFEROXAMINE; FERRITIN; FREE RADICAL; GROWTH DIFFERENTIATION FACTOR 15; HEME OXYGENASE 1; HEPCIDIN; IRON; IRON CHELATING AGENT;

BLOOD TRANSFUSION REACTION; CARDIOMYOPATHY; CHELATION THERAPY; CHRONIC INFLAMMATION; CONFERENCE PAPER; DIABETES MELLITUS; ENDOCRINE DISEASE; ERYTHROPOIESIS; HEART FAILURE; HUMAN; HYPOGONADISM; HYPOPARATHYROIDISM; HYPOTHYROIDISM; INTRAVASCULAR HEMOLYSIS; IRON OVERLOAD; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; SICKLE CELL ANEMIA; THALASSEMIA MAJOR; TISSUE INJURY;

ANEMIA, SICKLE CELL; BETA-THALASSEMIA; BLOOD TRANSFUSION; HUMANS; IRON; IRON OVERLOAD; TISSUE DISTRIBUTION;

EID: 73949098890     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630260903346627     Document Type: Conference Paper

References (62)

1. Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in b-thalassemia major. Blood. 2008;111:583-587.
2. Cohen A, Porter J. Transfusion and Iron Chelation Therapy in Thalassemia and Sickle Cell Anemia. Cambridge: Cambridge University Press; 2001.
3. Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136:501-508.
4. Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80:168-176.
5. Wolfe L, Olivieri N, Sallan D, et al. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med. 1985;312:1600-1603.
6. Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet 1989;2:27-30.
7. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major [see comments]. N Engl J Med. 1994;331:567-573.
8. Modell B, Mathews R. Thalassaemia in Britain and Australia. Birth Defects original article series 1976;12:13-29.
9. Buja LM, Roberts WC. Iron in the heart. Etiology and clinical significance. Am J Med. 1971;51:209-221.
10. Jensen PD, Jensen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood. 2003;101:4632-4639.
11. Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood. 2004;104:263-269.
12. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994;331:574-578.
13. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89:1187-1193.
14. Kirk P, Roughton M, Porter JB, et al. Cardiac T2& magnetic resonance for prediction of cardiac complications in thalassemia major. J Cardiovasc Magn Reson. 2009;1(Suppl. 1):O2:1-2.
15. Wood JC, Claster S, Carson S, et al. Vitamin D deficiency, cardiac iron and cardiac function in thalassaemia major. Br J Haematol. 2008;141:891-894.
16. Borgna-Pignatti C, Vergine G, Lombardo T, et al. Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol. 2004;124:114-117.
17. Angelucci E, Muretto P, Nicolucci A, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood. 2002;100:17-21.
18. Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med. 2000;343:327-331.
19. Porter JB, Huehns ER. Transfusion and exchange transfusion in sickle cell anaemias, with particular reference to iron metabolism. Acta Haematol. 1987;78:198-205.
20. Comer GM, Ozick LA, Sachdev RK, et al. Transfusion-related chronic liver disease in sickle cell anemia. Am J Gastroenterol. 1991;86:1232-1234.
21. Harmatz P, Butensky E, Quirolo K, et al. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood 2000;96:76-79.
22. Olivieri NF. Progression of iron overload in sickle cell disease. Semin Hematol. 2001;38:57-62.
23. Darbari DS, Kple-Faget P, Kwagyan J, Rana S, Gordeuk VR, Castro O. Circumstances of death in adult sickle cell disease patients. Am J Hematol. 2006;81:858-863.
24. Porter JB. Concepts and goals in the management of transfusional iron overload. Am J Hematol. 2007;82:1136-1139.
25. Westwood MA, Shah F, Anderson LJ, et al. Myocardial tissue characterization and the role of chronic anemia in sickle cell cardiomyopathy. J Magn Reson Imaging. 2007;26:564-568.
26. Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD. Myocardial iron loading in transfusiondependent thalassemia and sickle cell disease. Blood. 2004;103:1934-1936.
27. Vichinsky E, Butensky E, Fung E, et al. Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia. Am J Hematol. 2005;80:70-74.
28. Marx JJM, van Asbeck BS. Use of chelators in preventing hydroxyl radical damage: adult respiratory distress syndrome as an experimental model for the treatment of oxygen-radical-mediated tissue damage. Acta Haematol. 1996;95:49-62.
29. Kornbrust DJ, Mavis RD. Microsomal lipid peroxidation. 1. Characterisation of the role of iron and NADPH. Mol. Pharmacol. 1980;17:400-407.
30. Bacon BR, Tavill AS, Brittenham GM, Park CH, Recknagel RO. Hepatic lipid peroxidation in vivo in rats with chronic iron overload. J Clin Invest. 1983;71:429-439.
31. Myers BM, Prendergast FG, Holman R, Kuntz SM, LaRusso NF. Alterations in the structure, physicochemical properties, and pH of hepatocyte lysosomes in experimental iron overload. J Clin Invest. 1991;88:1207-1215.
32. Link G, Pinson A, Hershko C. Iron loading of cultured cardiac myocytes modifies sarcolemmal structure and increases lysosomal fragility. J Lab Clin Med. 1993;121:127-134.
33. Link G, Saada A, Pinson A, Konijn AM, Hershko C. Mitochondrial respiratory enzymes are a major target of iron toxicity in rat heart cells. J Lab Clin Med. 1998;131:466-474.
34. Zhao M, Laissue JA, Zimmermann A. Hepatocyte apoptosis in hepatic iron overload diseases. Histol Histopathol. 1997;12:367-374.
35. Jacob AK, Hotchkiss RS, Swanson PE, Tinsley KW, Karl IE, Buchman TG. Injection of iron compounds followed by induction of the stress response causes tissue injury and apoptosis. Shock. 2000;14:460-464.
36. Houglum K, Filip M, Witztum JL, Chojkier M. Malondialdehyde and 4-hydroxynonenal protein adducts in plasma and liver of rats with iron overload. J Clin Invest. 1990;86(6):1991-1998.
37. Parola M, Pinzani A, Casini E, et al. Stimulation of lipid peroxidation or 4-hydroxynonenal treatment increased procollagen (I) gene expression in human fat storing cells. J Biol Chem. 1993;264:16957-16962.
38. Bissell DM, Wang SS, Jarnagin WR, Roll FJ. Cell specific expression of transforming growth factor-ß in the rat liver. J Clin Invest. 1995;96:447-455.
39. Grootveld M, Bell JD, Halliwell B, Aruoma OI, Bomford A, Sadler PJ. Non-transferrin-bound iron in plasma or serum from patients with idiopathic hemochromatosis. Characterization by high performance liquid chromatography and nuclear magnetic resonance spectroscopy. J Biol Chem. 1989;264:4417-4422.
40. Evans RW, Rafique R, Zarea A, et al. Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera. J Biol Inorg Chem. 2008;13:57-74.
41. Gutteridge J, Halliwell B. Iron toxicity and oxygen radicals. Baillieres Clin Haematol. 1989;2:195-256.
42. Brissot P, Bolder U, Schteingart CD, Arnaud J, Hofmann AF. Intestinal absorption and enterohepatic cycling of biliary iron originating from plasma non-transferrin-bound iron in rats. Hepatology. 1997;25:1457-1461.
43. Link G, Pinson A, Kahane I, Hershko C. Iron loading modifies the fatty acid composition of cultured rat myocardial cells and liposomal vesicles: effect of ascorbate and alpha-tocopherol on myocardial lipid peroxidation. J Lab Clin Med. 1989;114:243-249.
44. Oudit GY, Sun H, Trivieri MG, et al. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med. 2003;9:1187-1194.
45. Liuzzi JP, Aydemir F, Nam H, Knutson MD, Cousins RJ. Zip14 (Slc39a14) mediates nontransferrin- bound iron uptake into cells. Proc Natl Acad Sci U S A. 2006;103:13612-13617.
46. Shah F, Westwood MA, Evans PJ, Porter JB. Discordance in MRI assessment of iron distribution and plasma NTBI between transfusionally iron loaded adults with sickle cell and thalassaemia syndromes. Blood. 2002;100:468a.
47. Walter PB, Fung EB, Killilea DW, et al. Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol. 2006;135:254-263.
48. Porter J, Cappellini M, El-Beshlawy A, et al. Effect of deferasirox (Exjade® ) on labile plasma iron levels in heavily iron-overloaded patients with transfusion-dependent anemias enrolled in the large-scale, prospective 1-year EPIC trial. Blood. 2008;112:Abstract 3881.
49. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090-2093.
50. Nemeth E. Iron regulation and erythropoiesis. Curr Opin Hematol. 2008;15:169-175.
51. Lin L, Valore EV, Nemeth E, Goodnough JB, Gabayan V, Ganz T. Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4. Blood. 2007;110:2182-2189.
52. Origa R, Galanello R, Ganz T, et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica. 2007;92:583-588.
53. Kattamis A, Papassotiriou I, Palaiologou D, et al. The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major. Haematologica. 2006;91:809-812
54. Shah FT. The relationship between non transferrin bound iron and iron overload in thalassaemia and sickle syndromes. MD Thesis, University of London; 2008.
55. Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007;13:1096-1101.
56. Sayani F, Bansal S, Evans P, Weljie A, Hider RC, Porter JB. Disease specific modulation of serum hepcidin: Impact of GDF-15 and iron metabolism markers in thalassemia major, thalassemia intermedia and sickle cell disease: A univariate and multivariate analysis. Blood. 2008;112:Abstract 3850.
57. Delaby C, Pilard N, Goncalves AS, Beaumont C, Canonne-Hergaux F. Presence of the iron exporter ferroportin at the plasma membrane of macrophages is enhanced by iron loading and down-regulated by hepcidin. Blood. 2005;106:3979-3984.
58. Knutson MD, Oukka M, Koss LM, Aydemir F, Wessling-Resnick M. Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin. Proc Natl Acad Sci U S A. 2005;102:1324-1328.
59. Jacolot S, Ferec C, Mura C. Iron responses in hepatic, intestinal and macrophage/monocyte cell lines under different culture conditions. Blood Cells Mol Dis. 2008;41:100-108.
60. Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002;8:1383-1389.
61. Nath KA, Grande JP, Haggard JJ, et al. Oxidative stress and induction of heme oxygenase-1 in the kidney in sickle cell disease. Am J Pathol. 2001;158:893-903.
62. Flanagan JM, Steward S, Hankins JS, Howard TM, Neale G, Ware RE. Microarray analysis of liver gene expression in iron overloaded patients with sickle cell anemia and beta-thalassemia. Am J Hematol. 2009;84:328-334.